Pacific Edge Reports Good Commercial Progress In Us Market And Strong Uplift In Sales Revenue

Cancer diagnostics company, Pacific Edge Limited (NZX:PEB) has announced a strong uplift in commercial revenue for the financial year ended 31 March 2015, as it continues to rollout its US sales and marketing strategy and build customer numbers.

The company, which launched its first bladder cancer diagnostic test, Cxbladder Detect, into the US in mid-2013, has identified North America as offering the most potential for the business in the short to medium term.

To support its growth strategy, Pacific Edge has ramped up investment into its US sales and marketing team and increased the number of User Programmes in all markets, a critical element in encouraging clinicians to adopt its products. The company is also putting significant investment into product development, specifically new Cxbladder products with Cxbladder Triage launched in late-2014, while also developing and protecting its IP on all of its cancer diagnostic technologies.

Read more here